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ABSTRACT 
Matrix metalloproteinases play a crucial role in the remodelling of the 
extracellular matrix through direct degradation of its structural proteins and control of 
extracellular signaling. The most common cause of ischemic brain damage is an 
atherothrombotic lesion in the supplying arteries. The progress of the atherosclerotic 
plaque development and the related thrombotic complications are mediated in part by 
matrix metalloproteinases. In addition to their role in the underlying disease, various 
members of this protease family are upregulated in the acute phase of ischemic brain 
damage as well as in the post-ischemic brain recovery following stroke. This review 
summarizes the current understanding of the matrix metalloproteinase-related 
molecular events at three stages of the ischemic cerebrovascular disease (in the 
atherosclerotic plaque, in the neurovascular unit of the brain and in the regenerating 
brain tissue). 
 
Keywords: extracellular matrix, atherosclerosis, blood-brain barrier, 
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INTRODUCTION 
Cardiovascular and cerebrovascular diseases are the most common cause 
of mortality in the developed countries (they are responsible for more than 50 % of 
the death events in Europe) (WHO statistics, Mortality database. 
http://www.who.int/healthinfo/morttables/en/) and in the majority of cases (more than 
90 %) an atherosclerotic plaque is the culprit lesion. The major characteristic of 
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atherosclerosis is a plaque formed in the intima layer of the arteries, which develops 
in the course of decades as a consequence of chronic inflammation. Some of the 
plaques contain low number of cells, but extensive extracellular matrix (ECM), and 
these are known as “stable plaques”, which resist mechanic forces and in clinical 
terms remain “silent” for long time. Other plaques are rich in cells and lipids 
(“unstable plaques”, which are ruptured easily and thus provoke thrombosis with 
eventual blood vessel occlusion and tissue ischemia). The stability of the plaque is 
tightly related to the proteolysis-dependent re-organization of the ECM based on the 
activity of matrix-metalloproteinases (MMP). 
The maintenance of the special metabolic environment in the central 
nervous system is based on the function of the neurovascular unit forming the 
interface between blood and parenchymal tissue in brain microcirculation. The 
endothelial cells, pericytes and astrocytes together with the ECM of this unit comprise 
a highly selective barrier between blood and brain, the blood-brain barrier (BBB) (1). 
The cellular interactions in the neurovascular unit induce unique differentiation of the 
brain microcirculatory endothelial cells, which are fenestration-free, joined together 
through tight junctions and anchored through their integrin receptors to the underlying 
basal lamina. Similarly to the rest of the brain tissue, which accounts for 20 % of the 
oxygen consumption in the whole body (2), the neurovascular unit is also very 
sensitive to ischemic insults, which cause cellular dysfunction. The post-ischemic 
disruption of the BBB results in diffusion of small osmotically active molecules and 
plasma proteins with consequent brain edema. However, the ECM of the basal lamina 
composed of type IV collagen, laminin, fibronectin, thrombospondin, entactin, 
proteoglycans (3) would not allow the leakage of cellular elements from blood. Thus, 
the frequent complication of the ischemic brain damage, the haemorrhagic 
transformation of an infarct, which occurs in 15 – 45 % of patients with cerebral 
infarction (4), can be explained only with concomitant degradation of the ECM 
structure. The proteases capable of performing this task at this location also belong to 
the family of MMPs.  
The repair process in the penumbra zone of the post-ischemic brain is 
accompanied by axon regeneration and maturation of progenitor cells. Recent data 
evidence the contribution of MMPs to this repair process, as well as to the 
revascularization of the affected tissue. This review discusses the role of MMPs in the 
abovementioned three stages of the cerebrovascular disease (the culprit lesion in the 
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arteries, the immediate post-ischemic brain damage and the post-ischemic tissue 
remodelling in the brain). 
 
STRUCTURE AND CLASSIFICATION OF MMPs 
Since the identification of collagenase-1 in the tail of metamorphizing 
tadpole (5) 23 different MMPs have been described in humans. All MMPs show 
structural homology to collagenase-1, which according to the present nomenclature is 
named MMP-1. Two structural domains are common for all MMPs: the Zn2+-binding 
sequence (HEXGHXXGXXH) in the catalytic domain and the cystein-lock in the pro-
peptide, which binds the active site Zn2+ through the PRCGXPD sequence in the 
zymogens and keeps the pro-MMPs in inactive form. Most of the MMPs contain two 
more common structures: the hinge region and the hemopexin domain, which 
participate in the initial binding of collagen fibers, the unwinding of their triple 
helices and the positioning of the separate polypeptide chains in the active site of the 
protease. Most MMPs are released in soluble form from the cells, but some of them 
function in membrane-bound form (membrane-type MMP, MT-MMP). The MMPs 
can be classified in 6 groups according to their relative substrate specificity, which is 
related to their primary and domain structure (Table 1) (reviewed in Ref. 6). 
 
REGULATION OF MMP ACTIVITY (gene expression, activation, 
inhibition) 
The common biological functions of MMPs are related to the 
reorganization of the ECM structure and the cell-matrix interactions in the course of 
tissue remodelling or regeneration as well as to the activation of signal peptides. 
These functions require stringent spatiotemporal control of the MMP activity, so that 
these enzymes can accomplish their tasks, but the detrimental effects of their 
propagation are restricted. Most MMPs are released immediately following their 
synthesis without storage and accordingly the regulation at transcriptional level is of 
primary importance for the appropriate MMP activity in the tissues. 
The regulatory region of some MMPs contains an activator protein 1 (AP-
1) binding site, where the heterodimers of c-fos and c-jun gene products bind (7), as 
well as a nuclear factor  B (NFB) binding site (8). The induction and activation of 
these gene products are under the control of cytokines (interleukins, tumor necrosis 
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factor-, interferons) and growth factors (epithelial, fibroblast growth factor), which 
can stimulate the expression of MMP-9 through activation of signaling pathways 
including a cascade of tyrosine and serine/threonine protein kinases as recently 
reviewed by Dong et al. (9). The expression of MMP-1 depends also on the presence 
of substrate: type I collagen binds to a cell surface tyrosine-kinase receptor with a 
discoidin domain, which is activated by native collagen and inhibited by partially 
digested collagen (10,11). Thus, MMP-1 is repressed by its own product. MMP-8 and 
MMP-9 in neutrophil granulocytes and MMP-12 in macrophages are exceptions from 
the general rule, because after their synthesis they are stored in secretion granules and 
released later by various triggers (e.g. inflammatory mediators, thrombin). Thus, these 
MMPs are present in the leukocytes, but in sequestered form and can exert their 
effects only at sites of inflammation. 
Because MMPs are produced in zymogenic form, their release does not 
result in automatically proteolytic activity. The sulfhydryl group of a cystein residue 
in the propeptide binds the active site Zn2+ and blocks it. The Cys-Zn2+ interaction 
should be disrupted for the activation of the proenzyme either by proteolytic or 
conformational modification, which results in binding of a water molecule as a fourth 
ligand of the Zn2+ for the attack on the target peptide bond in the MMP-substrate. The 
activation proceeds through two stages. At first, a portion of the propeptide is 
removed by partial proteolysis (usually catalyzed by a serine protease) or a chemical 
agent (an in vivo relevant molecular species may be peroxinitrite formed in the 
reaction of NO and O2-) which destabilizes the Cys-Zn2+ bond allowing water to bind 
the active site, which gains partial activity in this way (12). In the second stage, this 
partially active MMP autocatalytically removes the remnant propeptide (alternatively 
another MMP can catalyze this step) as a result of which the active site adopts its 
maximally active conformation. 
In the case of MT-MMP the initial activation step is catalyzed by the 
intracellular serine protease furin and thus when these enzymes are translocated to the 
plasma membrane, they are already fully active. The MT-MMPs take part in the 
activation of other MMPs in the extracellular space contributing to the tightly 
controlled pericellular remodelling of the ECM. In the case of soluble MMPs the first 
activation step occurs out of the cell, but it is also restricted to the pericellular space. 
For instance, polarized expression of urokinase receptor on the cell surface promotes 
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plasminogen activation by urokinase at distinct sites of the plasma membrane and the 
generated plasmin activates pro-MMPs in the near-by pericellular compartment (13). 
The action of MMPs is restricted in time and space by their endogenous 
inhibitors, which belong to the four-member protein family of tissue inhibitors of 
metalloproteinases (TIMP-1, 2, 3, 4) present in the extracellular space at much higher 
concentrations than the MMPs  (14). TIMPs are 20 – 29 kDa proteins, the N- and C-
terminal domains of which have distinct functions. The free -amino group of the N-
terminal Cys as well as its carbonyl group form coordination bonds with the active 
site Zn2+ of the MMPs, whereas the N-terminal Cys-Thr-Cys-Val-Pro peptide is 
tightly aligned to the substrate binding site of the enzyme. The C-terminal domain 
contributes to the specificity of the TIMP, e.g. the C-terminal of TIMP-1 binds with 
higher affinity to the hemopexin domain of MMP-9 than to MMP-2, whereas TIMP-2 
shows a reverse order of affinity. TIMPs restrict the action of the MMPs, but the 
TIMP-MMP complexes are reversible. Thus, their eventual elimination requires one 
more inhibitor, 2-makroglobulin (2-M) from blood plasma. MMPs cleave a peptide 
bond in the reactive site of 2-M followed by a conformational change in the 
molecule of the inhibitor, which thus entraps the protease (15). The 2-M-MMP 
complexes are then eliminated from circulation through scavenger receptor mediated 
endocytosis in the macrophages. 
If present at low, non-saturating concentrations, TIMPs act as cofactors in 
the proMMP activation. Playing this role the N-terminal domain of TIMP-2 binds the 
active site of MT1-MMP, whereas the C-terminal domain of the same TIMP-2 
molecule can bind the hemopexin domain of a proMMP-2. In this way TIMP-2 
converts some of the MT1-MMP molecules to proMMP-2 receptors, which anchor the 
zymogens and present them for more efficient activation by other, TIMP-free MT1-
MMP molecules, which act as proMMP activators (16). Similarly, TIMP-3 binds to 
heparan-sulfate and presents the proenzymes to their activators (17). 
 
THE ROLE OF MMPs IN THE ATHEROSCLEROTIC LESIONS 
Ischemic stroke is typically provoked by acute thrombosis over ruptured 
atherosclerotic plaque resulting in complete or partial occlusion of the affected artery. 
The most common type of atherosclerotic lesion is the atheroma composed of a lipid 
core and a thin fibrous cap comprising smooth muscle cells and ECM rich in type I 
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and III collagen. If the cap is disrupted, blood infiltrates the core region and the 
activation of platelets by ECM components triggers thrombus formation. Thus, the 
stability of the atherosclerotic plaques depends primarily on the structural integrity of 
the fibrous cap. The ECM of the atheroma undergoes continuous remodeling as 
balanced protein synthesis and degradation with MMPs on the proteolytic side of this 
balance. Strong evidence supports the contribution of MMPs to the instability of the 
plaque. Quantitative analysis of the MMP content in human carotid plaques obtained 
from endarterectomy indicates definite increase in the MMP-9 antigen and mRNA 
(18). The concentration of MMP-9 correlates with the histological signs of plaque 
instability (plaque rupture, intraplaque hemorrhage) and the severity of clinical 
symptoms (spontaneous cerebral particulate embolization detected with transcranial 
Doppler) (18). MMP-1 protein and mRNA are also detected in carotid endarterectomy 
specimens (19). The level of MMP-1 correlates with the areas of hemorrhage in the 
plaques (19). The cleavage of the native triple collagen helix is the unique property of 
three MMPs (MMP-1, MMP-8 and MMP-13). The overexpression of all three of them 
has been shown in vulnerable human atheroma. In addition to MMP-1, MMP-13 co-
localizes with cleaved collagen in the plaques with macrophages and endothelial cells 
as potential sources of this protease (20). Although MMP-8 is typically expressed by 
neutrophils, macrophages in human carotid atheroma have also been shown to 
produce MMP-8, which co-localizes with cleaved collagen (21).  
The atherosclerotic plaque is a focus of chronic inflammation and 
overexpression of MMPs in the plaque is related to the inducing effects of 
inflammatory mediators. Tumor necrosis factor- and interleukin-1 trigger MMP-1, 
MMP-3 and MMP-9 release in smooth muscle cells (22). Macrophages are also an 
important source of MMPs and the lipid-load stimulates the production of MMP-1 
and 3 in macrophage-derived foam cells (23), whereas tumor necrosis factor- and 
interleukin-1 induce MMP-9 (24). In addition to these inducing effects, the local 
generation of reactive oxygen species by inflammatory cells in the atherosclerotic 
plaques supports the activation of the pro-enzyme forms of the MMPs (25). 
Inflammatory mediators contribute not only to the overexpression of MMPs in the 
vulnerable plaques, but also to the impairment of collagen synthesis in the fibrous cap 
and thus to plaque instability. Interferon- has been shown to suppress the expression 
of collagen genes in smooth muscle cells (26). In the fibrous cap the amount of type I 
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collagen is definitely lower around T-cells producing interferon- (27). At basal level 
the synthesis of ECM molecules by smooth muscle cells is limited, but MMPs may 
promote a switch from a contractile to a synthetic phenotype in these cells. 
Collagenase treatment stimulates a 25-30-fold increase in the collagen synthesis 
(primarily type I) by smooth muscle cells (28). The defect in this phenotypic switch 
may explain some surprising data that the collagen content in atherosclerotic lesions 
of MMP-9 knock-out mice is lower than in the wild-type mice (29). In this respect the 
substrate preferences of the MMPs may be of special importance; the proteolytic 
activity of MMP-9 on type IV collagen seems to be a prerequisite for basal membrane 
breakdown and consequently for the migration and phenotypic switch of smooth 
muscle cells in atherosclerotic lesions. In line with this role of MMPs, the neointimal 
thickening of carotid arteries in a murine blood-cessation model requires migration of 
cells that is preceded by increase in the MMP-9 activity (30). Smooth muscles cells 
from MMP-9 knock-out mice show decreased migratory activity (31). Thus, the role 
of MMPs in the atherosclerotic plaques should not be oversimplified. Clearly, the 
MMPs promote instability of the atherosclerotic plaques through degradation of ECM 
components, but their activity may also favor the penetration of proliferating cell into 
the neointima. The increase in the cell number in the area of the atheroma, however, 
favors the synthesis of new ECM components and thus may improve the stability of 
the plaque. 
As discussed in the preceding section, the proteolytic activity of MMPs is 
under the control of TIMPs. Accordingly, the fate of the atherosclerotic plaque is 
affected by the local expression of TIMPs, too. TIMP-1 and TIMP-2 are constitutively 
secreted by smooth muscle cells in normal and atherosclerotic arteries (32). 
Macrophages in the atherosclerotic plaques express TIMP-1, TIMP-2 and TIMP-3 
(33). Importantly, the triggers of TIMP expression differ from those for MMP 
expression. The constitutive expression of TIMP-1 and TIMP-2 is not affected by the 
cytokines discussed above as inducers of MMP (tumor necrosis factor- and 
interleukin-1). In contrast, growth factors known to promote neointima formation 
(platelet-derived growth factor, transforming growth factor-) promote TIMP-1 and 
TIMP-3 production by atherosclerotic lesion-associated macrophages (33). Thus, 
these fibrogenic growth factors may mediate a defense mechanism against plaque 
rupture. 
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EVIDENCE FOR THE ROLE OF MMPs IN THE STROKE-RELATED 
DISRUPTION OF THE BLOOD-BRAIN BARRIER 
Solid experimental and clinical observations support the concept for the 
involvement of the MMPs in the haemorrhagic transformation of the ischemic stroke 
(34). The earliest data come from direct intracerebral injection of MMP (collagenase), 
which provokes hematoma and brain edema in rats (35,36).  After experimental 
cerebral vascular occlusion and reperfusion in rats, MMP-2 activity increases in the 
brain tissue and in parallel the BBB opens to proteins (37). Experimental ischemia 
causes elevation of the MMP-9 activity in the brain of mice (38) and rats (39), 
whereas MMP inhibitors reduce the infarct volume in rats (39) and the thrombolysis-
induced haemorrhage after thromboembolic stroke in rabbits (40). The activity of 
MMP-2 and MMP-9 in the brain and of MMP-9 in the blood plasma increases during 
focal cerebral ischemia in baboons (41). Strong correlation exists between the size of 
brain lesion and the level of MMP-9 in blood of patients with acute ischemic stroke 
(recently reviewed in 42), middle cerebral artery occlusion or cardioembolic stroke 
independently of the applied fibrinolytic therapy (43,44). In addition, the increased 
MMP-9 level in blood is a predictor for poor outcome and hemorrhagic complications 
following tissue-type plasminogen activator (tPA) treatment of ischemic stroke (45). 
MMP-9 knock-out mice are protected against injury in transient focal ischemia and 
the BBB disruption following ischemic insult is attenuated in the MMP-9 knock-out 
mice compared to the wild-type (46,47), but MMP-2 gene knock-out does not provide 
neuroprotection in mouse models of permanent and transient middle cerebral artery 
occlusion (48). MMP-2 and MMP-9 have been shown to differentially mediate 
disruption of the BBB and neuronal damage after cerebral ischemia. These two 
proteases may play different roles in human ischemic stroke. Increase in plasma 
MMP-2 is observed only in patients with lacunar stroke early (within 12 hours), and is 
related to better outcome. In contrast, increase in plasma MMP-9 seems to be late (at 
day 7) and related to more severe stroke (49). 
BBB opening during focal cerebral ischemia/reperfusion has long been 
considered to follow a biphasic time course. In a transient middle cerebral artery 
occlusion rat model, the initial opening of the BBB occurred 3 hours after reperfusion, 
and increased activation of MMP-2 correlated with the early opening of the BBB. The 
early degradation of occludin and claudin-5 seems to be associated with MMP-2 
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activity (50). Experimental data demonstrate greater increase in MMP-2 than in 
MMP-9 at 3 hours, with increased expression of furin and MT1-MMP, the activators 
of MMP-2. In contrast, there was no increase in MMP-2 mRNA and activity, while 
MMP-9 mRNA and activity increased at 24 hours of reperfusion, suggesting a role of 
MMP-9 in mediating the second, delayed opening of BBB after ischemic stroke. 
Although MMP activity is minimal at basal level in brain, multiple cellular 
sources exist in the central nervous system. Immunohistochemistry data evidence 
localization of MMP-2 in astrocytes, MMP-3 in microglial cells and MMP-9 in 
endothelial cells around experimentally induced ischemic core in rat brain (51). Data 
from cell culture of human capillary endothelial cells (HBEC) evidence that these 
cells produce and secrete MMP-9 (52). It seems that the type of MMP expressed in 
different brain cells shows species specificity. Our data (52) on the gelatinolytic 
activity in the supernatants of human brain capillary endothelial cells and their 
immunoreactivity confirm that these cells express MMP-9, but not MMP-1, -2, or -3 
in contrast to the reported expression of MMP-2 in rat brain capillary endothelial cells 
(53) and in agreement with the MMP-2 localisation in astrocytes around 
experimentally induced ischemic foci in rat brain (51). Although extrapolation of data 
from knock-out mice to the role of MMPs in human disease should be treated with 
due caution, mice data indicate that inflammatory cells, leukocytes and bone marrow-
derived cells appear to be an important alternative source of MMP-9 in stroke. 
Neutrophil leukocytes contain pro-MMP-9 in secretory granules, and the factors that 
promote degranulation of these cells are available in the ischemic brain. With the use 
of MMP-9 knockout and chimeric knockout (lacking MMP-9 in leukocytes or in 
resident brain cells) mice, the loss of BBB integrity and neuronal injury can be 
attributed to leukocyte MMP-9 during the initial 8 hours of reperfusion after focal 
stroke (54). Another similar study using chimera knockout mice showed that bone 
marrow cells derived MMP-9 contributes to BBB disruption and increase in infarct 
volume after reperfusion (55).  
 
TRIGGERS OF MMP ACTIVITY IN THE ISCHEMIC BRAIN 
Hypoxia on its own is a strong trigger of gelatinolytic activity in human 
brain endothelial cells, which according to the immunoblotting evaluation can be 
attributed to MMP-9 release. This effect is almost maximal at 4-h exposure to mild 
hypoxia and at this early time it is matrix-dependent (no effect in the absence of 
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collagen). The collagen-dependence of the MMP-9 expression is not surprising; 
similar dependence has been shown for other metalloproteinases (MMP-2, MT1-
MMP) from endothelial cells of different origin (56). Following reoxygenation for a 
period of 24 h and even 5 days the MMP-9 activity expressed early after the exposure 
to hypoxia is moderated down to the normoxic basal level independently of the 
matrix. Additional factors, however, may prolong the action of MMP-9: the specific 
activity in the conditioned media of cultured human brain endothelial cells indicates 
that the strongest trigger of the MMP-9 expression for the 24-h incubation period is 
the exposure to reactive oxygen (H2O2) after hypoxia (a 6-fold increase compared to 
the basal level) (52). H2O2 can be used as a stable reactive oxygen species to model 
the reperfusion phase after ischemic brain injury. Excessive production of H2O2 has 
been shown in postischemic reperfusion (57,58) and this H2O2 causes ATP-depletion 
and severe abnormalities in the ion (Na+, Ca2+) homeostasis of the affected neurons 
(59). At concentrations corresponding to the in vivo data reported for reperfused areas 
of ischemic rat brain (up to 100 M) (60), but still below the cytotoxicity threshold of 
H2O2 (61), H2O2 exerts its effects on the MMP-9 expression. The time-course of this 
hypoxia-induced and active oxygen-maintained MMP-9 expression in HBECs is in 
good agreement with the reported temporal pattern in ischemic brain (62) and this 
supports the concept that the microvascular endothelial cells can be the source of 
MMP-9 activity in the ischemic brain. 
The effect of MMPs depends strongly on the inhibitor potential in the 
extracellular space. The major natural inhibitor of MMP-9 is TIMP-1 and according 
to our data (52) the constitutive expression of this inhibitor is not affected by the 
triggers that stimulate the MMP-9 activity. Thus, it is justified to regard the changes 
in the MMP-9 activity as a result of changed expression or activation (against the 
background of constant inhibitor level). The other potential inhibitor, TIMP-2 is 
present in increased amounts in the conditioned media of HBECs following hypoxia 
and exposure to hydrogen-peroxide. Even in this situation, however, the concentration 
of the inhibitor in the medium (up to 2 nM) is an order of magnitude lower than the Ki 
for MMP-9 (40 nM), thus TIMP-2 cannot be taken into consideration as a relevant 
factor influencing MMP-9 in the medium. The profile of TIMPs produced in human 
brain microcirculatory endothelial cells resembles that in mouse (63) in contrast to rat, 
where only the expression of TIMP-2 has been reported (53). The constitutive 
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presence of TIMP-1 provides an additional link to the control of MMP-9 activity in 
posthypoxic inflammation loci. This inhibitor is preferentially degraded by 
polymorphonuclear leukocyte elastase (PMN-elastase) (64), a protease released by 
inflammatory cells. Thus, this leukocyte-derived protease can promote extracellular 
matrix degradation in the cerebral microvasculature in at least three ways: through its 
own proteolytic action, induction of MMP-9 (see later) and modulation of the MMP-9 
inhibitory system. 
The oxidative stress-dependent MMP-9 induction is accompanied by a 
significant increase in the amount of NF-B localized in the nuclei. Hypoxia or H2O2 
separately and their combination significantly elevate the nuclear level of NF-B. The 
variations in the effects of these three triggers can be attributed to their controversial 
impact on the activation of NF-B and the redox-state of the intracellular glutathione. 
The DNA-binding of the activated NF-B is inhibited by oxidized glutathione, but the 
concentration of the latter decreases in hypoxia (65) with consequent optimal NF-B 
response. H2O2 directly activates NF-B, but when applied in the post-hypoxic state it 
oxidizes glutathione and this shift in the redox state partially reverses the observed 
stimulation of NF-B in hypoxia. The functional role of the NF-B in the 
transcription is supported by the decreased susceptibility of NF-B to the monoclonal 
antibody specific for the transactivation domain of NF-B (52). Under certain post-
hypoxic conditions the COOH-transactivation domain is functionally involved (and 
thus prevented from binding to detection antibodies) in interactions with the 
transcriptional machinery resulting in sustained MMP-9 gene expression. At basal 
state the NF-B is present in a latent form in the cytosol as a heterodimer with an 
inhibitory protein (IB) and the destruction of the latter by the 20S proteasome allows 
the nuclear translocation of NF-B. When the activation of NF-B is blocked with an 
inhibitor of IB degradation (MG132), the post-hypoxic MMP-9 response to H2O2 is 
blunted in parallel to a decrease in the NF-B localized in the nucleus. It is notable 
that the effect of hypoxia/H2O2 on the nuclear NF-B level and the cytoplasmic IB is 
sustained for a period as long as 24 h after 4-h hypoxia followed by a bolus of H2O2. 
These temporal changes in the NF-B/IB levels and the accompanying MMP-9 
activity derived from human brain capillary endothelial cells are in good agreement 
with the time-course of the MMP-9 changes observed in the animal models and 
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patients discussed above. This supports the role of the described NF-B signal 
transduction circuit in the control of the oxidative stress-dependent MMP activity in 
brain after ischemic insults.  
Data from our laboratory (66,67) show that a set of serine proteases 
(thrombin, plasmin, miniplasmin and PMN-elastase) cause extravasation of 
circulating phase-borne tracer in a rat brain-perfusion model indicating that these 
proteases definitely change the structure of the BBB. This effect is related to the 
protease activity; if the active site of the enzymes is irreversibly blocked, the integrity 
of the BBB is not disturbed. These proteases are presumably active participants in the 
ischemic insult in brain. Thrombin is involved in the acute thrombus formation over 
ruptured atherosclerotic plaques or it is entrapped in active form in the fibrin mesh of 
cardioemboli and thus it can be carried downstream to the cerebral microvasculature. 
The ischemic brain injury is accompanied by inflammatory response in the ischemic 
locus and penumbrial area, a part of which is the infiltration by leukocytes releasing 
PMN-elastase and MMPs. In brain microcirculation plasmin may be generated from 
blood-borne plasminogen by tPA or urokinase produced in the microvascular 
endothelial cells. Alternatively, treatment of ischemic stroke with plasminogen 
activators is a potential source of plasmin. Only fibrin-bound proteases are efficient in 
fibrin solubilization, since free enzymes are not protected against blood plasma 
protease inhibitors. Thus, lysis of the occluding thrombus requires massive generation 
of fibrinolytic enzymes to escape the regulation by the plasma protease inhibitors at 
least in the immediate vicinity of the fibrin clot. If the amount of fibrinolytic enzymes 
increases over the locally available concentration of plasma protease inhibitors, they 
may bind to endothelial cells in the downstream vascular bed, where they are also 
protected against the plasma protease inhibitors. Reversible, specific and saturable 
binding of plasmin, thrombin and PMN-elastase to the brain capillary endothelial cells 
has been documented (66,67). The affinity (in terms of dissociation equilibrium 
constant) of these proteases to the capillary endothelial cells is in the range of 10-7 M. 
The molecular nature of the cellular binding site has not been identified. The fact that 
thrombin, plasmin and PMN-elastase affect the morphology of the brain capillary 
endothelial cells in a similar way (all of them cause rapid contraction) raises the 
possibility for a common event in their action. Interference of plasmin with the 
thrombin effects on a different cell-type (glioma cells) has been reported (68) and this 
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has been interpreted as a result of the cleavage of the thrombin-receptor by plasmin. 
Similar interplay of enzymes on a single molecular target is a possibility for the 
phenomena observed in brain capillary endothelial cells (the number of binding sites 
for the different proteases varies within a very narrow range). The family of 
proteolytically activated cellular receptors (PAR) is a potential candidate target for the 
action of the discussed serine proteases.  
A highly specific serine protease, tPA is found mostly in blood, its main 
function is to convert plasminogen to plasmin. In the brain, tPA has been shown in the 
endothelial cells of the BBB, where it may regulate BBB permeability and vascular 
tone. This enzyme is also expressed by neurons and microglia, and causes microglial 
activation and neuronal death after injury (69). In the brain, tPA is regulated by 
neuroserpin, a member of the serine proteinase inhibitor family. In rodent stroke 
models, endogenous tPA activity in the brain is induced as early as 1 hour after focal 
cerebral ischemia, and is present in the perivascular tissue and the vessel wall. tPA 
inhibition by neuroserpin decreases BBB disruption, edema, neuronal death. Levels of 
MMP-9 in ischemic brain are significantly reduced in tPA knock-out mice compared 
to wild-type animals, exogenous tPA administration increases MMP-9 response to 
wild-type levels (70). tPA increases MMP-9 expression and activity resulting in the 
degradation of claudin-5 and development of cerebral edema (71). It has been shown 
that MMP-3 plays a role in the intracranial bleeding after tPA treatment of stroke in 
mice. MMP-3 expression is enhanced in the neurons of the ischemic hemisphere, but 
upregulation can be seen in the endothelial cells after tPA treatment. In vitro, tPA 
induces MMP-3 in murine brain endothelial cells (72,73). tPA can bind to LRP (LDL 
receptor related protein), which can be found in the brain neurons and in perivascular 
astrocytes. Injection of recombinant tPA into the cerebrospinal fluid increase BBB 
permeability, and this effect is reversed by blocking LRP using anti-LRP antibodies 
(74). Recombinant tPA stimulates MMP-9 expression in cultured human brain 
endothelial cells, and this effect is reduced when the cells were treated with siRNA to 
suppress LRP. tPA induces MMP-3 in cultured murine brain endothelial cells, and 
this induction is prevented by inhibition either of LRP or NF-κB activation (73). 
These data suggest that tPA can induce MMP-9 and MMP-3 via LRP/NF-κB with 
consequent BBB damage. 
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The enzyme-induced endothelial cell contraction and the consequent gap 
formation in the endothelial lining of the brain capillaries could essentially modify the 
permeability of the BBB. In addition to their direct effect on cell morphology 
thrombin and PMN-elastase are strong triggers of the MMP-9 expression in HBECs. 
Plasmin does not induce MMP-9 in brain endothelium, but its role in the partial 
proteolytic activation of proenzyme is known (6). The role of these proteases in the 
hemostatic balance helps the interpretation of their effects on the expression of MMP 
activity in brain microcirculation. Fibrinogen is converted by thrombin to form fibrin, 
the solid matrix of hemostatic plugs, but it is not digested by catalytic amount of 
MMP-9 in solution (75). Thus, in vivo MMP-9 is not expected to interfere with the 
basic haemostatic function of thrombin and to contribute to the propagation of the 
haemorrhage. In contrast, higher pericellular concentrations of MMP-9 could 
contribute to the removal of fibrin deposits (76) and consequently counteract the clot-
forming action of thrombin. Altogether, the thrombin-induced MMP-9 response of 
brain endothelium may serve the protection of the cerebral microvasculature against 
fibrin deposition under physiological conditions, but in ischemic stroke especially of 
cardioembolic origin thrombin reaching the capillary endothelium may contribute to 
the disruption of the vascular integrity with consequent haemorrhagic transformation. 
Thus, paradoxically under hypoxic conditions thrombin generates a pericellular zone 
of enhanced fibrinolysis in the BBB. This pathophysiological impact of thrombin is 
further enhanced by the locally formed plasmin and the PMN-elastase released from 
inflammatory cells through their direct fibrinolytic action and induction/activation of 
MMP-9. 
In addition to the serine proteases discussed above, activation of MMPs in 
the brain is related to the effects of NO (12). As a part of the nitrosative and oxidative 
stress following cerebral ischemia and reperfusion, the level of NO in the affected 
brain areas is high (77). NO reacts with cysteine residues in proteins and the resulting 
S-nitrosylated derivative modifies the function of the proteins. In the case of 
proMMPs this nitrosylation is followed by oxidation of the Cys thiol group to sulfonic 
acid, which disrupts the bond between the pro-peptide Cys and the active site Zn2+ 
with subsequent activation of the enzyme. In experimental mouse model of ischemic 
stroke and reperfusion elevated MMP-9 activity can be detected, which is abrogated 
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in neuronal NO synthase knock-out mice or in wild-type mice treated with NO 
synthase inhibitor (12). 
 
 
TARGETS OF MMPs IN THE CNS 
The pericellular proteolysis targets a large range of matrix structural 
proteins, but it also affects the availability of the active form of signal molecules and 
the function of cellular receptors. The disruption of the extracellular matrix causes 
cell detachment and a special form of apoptotic cell death called anoikis (78, reviewed 
in 79).  
An essential element of the barrier function of brain capillary endothelium is 
the tight junctions between the cells, the structure of which is based on zonae 
occludens-1 (ZO-1) protein (80). ZO-1 is a substrate of MMP-9 and following 
ischemic brain injury its extensive degradation can be detected, 24 h after the 
ischemic insult the ZO-1 level in the affected area is less than 30 % of the baseline 
(46). MMP-9 was demonstrated to degrade also occludin and claudin-5 in focal 
cerebral ischemia (50). The role of MMP-9 in the post-ischemic disruption of the 
brain endothelial tight junctions is supported by the lack of ZO-1 degradation in 
MMP-9 knock-out mice under the same conditions of ischemic insult. Several 
proteins of the basal lamina in brain microcirculation are also degraded following 
ischemic damage (laminin, collagen type IV and cellular fibronectin) (81), all of 
which are substrates of MMP-9. Collagen degradation after cerebral ischemia might 
be in part caused by MMP-13 (43). Another matrix metalloproteinase, MMP-3 can 
also be activated after ischemia in rat brain, causing cleavage the cerebral matrix agrin 
(82). MMP-3 can contribute to BBB opening during neuroinflammation after intra-
cerebral lipopolysaccharide injection in mice. MMP-3 knock-out mice showed less 
degradation of tight junction proteins (occludin, claudin-5, laminin-alpha-1), 
compared to wild-type animals (83). 
Although the endothelial cells are a major source of MMP-9 in the brain and 
so the tight-junction and basal lamina proteins are easily accessible to the protease, 
the role of MMP-9 in the degradation of brain extracellular proteins is not restricted to 
the BBB. The myelin basic protein is a known substrate of MMP-9 and its 
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degradation accompanies the ischemic damage of the white matter. MMP-9 knock-out 
mice, which have reduced lesion size after transient ischemia, are protected against 
degradation of the myelin basic protein too (46). Similarly to the situation in BBB the 
proteolysis in the white matter is not general, but has specific targets; two other 
myelin proteins (PLP and DM20) are not affected in the ischemic regions. 
The MMP-9 induced neuronal apoptosis (12) may be related to the 
degradation of basement membrane proteins in brain (84). MMP-9 activity is co-
localized with laminin early after transient ischemia in mouse brain and progressive 
loss of laminin immunoreactivity is observed later, which is prevented by MMP 
inhibitors. The disruption of the cell-matrix connection caused by the laminin 
degradation is suggested as a trigger of neuronal apoptosis (84). This hypothesis is 
supported by the effect of a laminin-blocking antibody, which abrogates the protective 
effects of MMP-inhibitors in the early post-ischemic brain damage. Detachment from 
the matrix proteins triggers a suicide cell program called anoikis (85). The 
intercellular junctions and the matrix-cell interactions definitely act as a survival 
signal in capillary endothelial cells (86) and thus the degradation of ZO-1 and laminin 
by MMP-9 can trigger programmed cell death in the post-ischemic brain areas. 
An additional role of MMPs at the site of ischemic brain injury is the local 
control of the inflammatory reaction. MMP-9 cleaves the 6 N-terminal amino acids of 
interleukin-8 and thus converts it to a ten-fold more potent chemoattractant of 
neutrophil leukocytes (87). On their own neutrophils represent a source of MMP-9 
and MMP-8, thus forming a self-accelerating circuit promoting inflammation and 
further increase in the local MMP activity. Another chemokine, stromal cell-derived 
factor 1 (SDF-1) is cleaved at position 4-5 by MMP-1 -,2, -3, -9, -13 and 14, 
following which it loses its chemoattractant activity (88). The resultant des(1-4)-SDF-
1, however, adopts strong neurotoxicity (89). The cleaved SDF-1 triggers apoptosis in 
neurons in vitro and following stereotactic implantation in the striatum of mice it 
provokes massive neuronal loss accompanied by hypertrophy of microglia and 
astrocytes (gliosis) seen phenotypically as behavioral and motor abnormalities. 
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MMPs in BRAIN REGENERATION FOLLOWING ISCHEMIC INSULT 
The upregulation of MMPs in the early (up to 24 h) period after an ischemic 
insult has detrimental effects on the BBB and the affected neurons, but their function 
may be beneficial later, in the stage of tissue regeneration and remodelling. 
The subventricular zone of the lateral ventricles and the subgranular zone of 
the hippocampus are critical structures for neurogenesis in adult brain. Increased 
neurogenesis can be triggered by central nervous system insults such as stroke or 
trauma. Stroke leads to the expansion of subventricular zone and produces BrdU-
labeled immature cells and doublecortin-positive neural precursors. At 2 weeks after 
stroke in mice, MMP-9 was enhanced in the subventricular zone and colocalized with 
BrdU and doublecortin-positive neuroblast cells (90). MMP-3 also participated in 
neurogenesis, and together with MMP-9 mediated the differentiation and chemokine-
induced cell migration of adult neural or stem progenitors (91). Inhibition of MMPs 
reduced the extension of neuroblast signals that extended from the subventricular 
zone into the damaged striatum. After middle cerebral artery occlusion/reperfusion in 
rat, the number of MMP-13 positive neurons, mainly in the border zone of the infarct, 
increased at day 3, peaked after a week, and 14 days later it was still higher than in 
normal tissue (92). The observed co-localization of the proliferation marker BrdU and 
MMP-13 suggests that the presence of newborn neurons is related to MMP-13 
activity. The post-ischemic tissue regeneration involves not only a cellular response, 
but also reorganization of the ECM proteins, as seen in the accumulation of aggrecan, 
a histomorphogenetic proteoglycan in brain, around MMP-13 positive cells in the 
periinfarct zone (92). These data indicate that MMPs may contribute to endogenous 
repair mechanisms by helping the migration and proliferation of neuroblasts after 
stroke. 
In contrast to the situation in the acute (up to 24-48 h) post-ischemic stage, 
when the increase in MMP-9 activity is associated with the endothelial cells of the 
BBB, on days 7-14 after transient focal brain ischemia in rats MMP-9 expression is 
localized to neurons and astrocytes in the peri-infarct zone (93). Rat endothelial cell 
antigen-1 (RECA-1) is a marker of microvessel endothelial cells and it is upregulated 
in the peri-infarct area on days 10-14 after a 2-hour transient focal ischemia. The 
protein product of the Egr1 immediate early gene is associated with neuron sprouting 
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and its expression is also stimulated in this later stage after a stroke. Both RECA-1 
and Egr1 responses are abrogated by MMP inhibitors applied at the time preceding 
their maximal expression suggesting a causative relation between the MMP-9 
expression and the tissue recovery after an ischemic insult. MMP inhibitors applied 
later than day 7 after the transient focal brain ischemia significantly increase the 
infraction size and the occurrence of delayed gross cerebral hemorrhage (93). MMP-9 
is not neuroprotective on its own; through the disruption of the cell-matrix 
connections it even induces anoikis as discussed above. Thus, its beneficial effects are 
presumably related to its role in the delayed neurovascular remodelling. An important 
step in brain recovery is the reformation of damaged myelin, which is based on the 
oligodendrocyte precursor migration, process extension and ensheathment of axons by 
these processes. Cultured oligodendrocytes from MMP-9 knock-out mice have 
diminished capacity to reform such processes (94). The NG2 chondroitin sulfate 
proteoglycan is inhibitory on axon regeneration, because the NG2-rich matrix is 
unfavourable for the maturation of progenitor cells into oligodendrocytes (95). MMP-
9 degrades NG2 and thus it promotes remyelination as a part of the brain recovery 
process (95). Phosphorylated neurofilament M is a marker of regenerative elongation 
of axons and it is induced by MMP-9 treatment in a neuron cell-culture model, 
whereas anti-MMP-9 antibodies inhibit it, supporting the role of MMP-9 in neuron 
regeneration (96). 
In addition to the neuronal recovery, MMP-9 is engaged in the vascular 
remodelling through its role in the regulation of angiogenic factors. Vascular 
endothelial growth factor (VEGF) is a potent inducer of angiogenesis. MMP-9 
provokes angiogenesis in organ culture (97) and in parallel VEGF is released in the 
medium. A proposed mechanism for this effect is the mobilization of VEGF from its 
bound form to an extracellular proteoglycan following proteolysis by MMP-9. The 
cerebral vascular perfusion is improved in the penumbra of the cortex as a result of 
VEGF infusion at 48 h after the ischemic insult in a rat stroke model (VEGF infusion 
at the onset of the acute stage, 1 h after the artery occlusion has detrimental effects, 
causing BBB leakage and gross hemorrhage) (98). This improved perfusion is due to 
the appearance of newly grown vessels in the penumbra. The functional neurological 
recovery of the rats exposed to VEGF infusion shows better results compared to non-
treated animals in the same rat stroke model. VEGF levels are elevated in the 
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penumbra 14 days after transient focal ischemia, coinciding with MMP-9 elevation 
(93). MMP inhibitors abrogate this VEGF response and increase the infarct volume, 
whereas exogenous VEGF treatment restricts the infarct size, even if MMP inhibitors 
are also applied. All these data support the concept that MMP-9 is an essential factor 
in the vascular recovery following ischemic stroke through VEGF-mediated effects. 
Not only MMP-9, but TIMPs can also affect angiogenesis. TIMPs can inhibit 
angiogenesis through MMP inhibition, as well as MMP-independent mechanisms 
such as interference with VEGF signaling. TIMP-2 has been shown to disturb 
intracellular phosphorylation and activation of VEGFR-2 (vascular endothelial growth 
factor receptor-2) (99), and TIMP-3 is able to block VEGF binding to VEGFR-2 
(100). 
In summary, the data accumulated in the last decade confirm well-defined 
functions of MMPs in the pathomechanism of ischemic stroke. In the atherosclerotic 
lesion the basic effect of MMPs is the degradation of ECM components with 
consequent instability of the plaques. Within the brain MMP activity is generally 
detrimental in the initial acute phase (within 24 h after the ischemic insult), but 
beneficial in the delayed recovery period (several days after the acute event) (Fig.1). 
The interplay of ischemia-related chemical factors (hypoxia, reactive oxygen species, 
NO), inflammatory mediators (IL-1, TNF-) and regulatory proteolytic activity 
(MMP-3, MT1-MMP, plasminogen/plasminogen activator system) results in massive 
activation of effector MMPs (MMP-9, MMP-13, MMP-2) in the ischemic brain areas. 
However, the same proteolytic actions appear essential in the regenerative remodeling 
of the post-ischemic brain tissue. This spatial and temporal pattern of MMP action 
should be considered with respect to the design of pharmacological intervention 
targeting these proteases. 
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Table 1. Major MMP classes based on structural characteristics and substrate 
preferences.  
 
MMP class Representative enzyme Structural features Substrates 
Collagenases MMP-1 
MMP-8 
MMP-13 
MMP-18 
 
PCHH type I, II and III 
interstitial collagen 
Gelatinases MMP-2 (gelatinase-A) 
MMP-9 (gelatinase-B) 
PCHH + three 
fibronectin-like 
domains for gelatin 
and laminin binding 
type IV collagen 
gelatin (denatured 
and partially 
degraded collagen) 
 
Stromelysins MMP-3 (stromelysin-1) 
MMP-10 (stromelysin-2) 
MMP-11 (stromelysin-3) 
 
PCHH proMMP activation 
ECM proteins 
Matrilysins MMP-7 (matrilysin-1)  
MMP-26 (matrilysin-2) 
PCHH without a 
hemopexin domain 
ECM proteins, pro-
-defensin, Fas-
ligand, pro-TNF-, 
cadherin E 
 
Membrane-
type MMPs 
MMP-14 
MMP-15 
MMP-16 
MMP-24 
 
MMP-17 
MMP-25 
PCHH + 4 TM 
domains 
 
 
 
PCHH + GPI anchor 
 
 
type I, II, III 
collagens 
proMMP-2 
Other MMPs MMP-12 (macrophage 
metalloelastase) 
PCHH elastin 
other ECM proteins
 
Abbreviations: TM, transmembrane; GPI, glycosyl-phosphatidylinositol; PCHH, 
propeptide – catalytic – hinge – hemopexin domains 
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Figure legend 
Fig. 1. Mechanisms of activation and biphasic roles of MMPs in stroke.  
 
Ischemia enhances proMMP-9 gene transcription through hypoxia, IL-1β, TNF-α and 
tPA. The proenzyme can be activated by multiple proteases, such as other MMPs, 
plasmin and by free radicals (ROS, NO). The early activation of the MMPs after 
stroke degenerates neurovascular matrix and BBB, disrupts cell-matrix homeostasis, 
and causes neuronal death, edema, hemorrhage. Delayed actions of these enzymes 
involve neural and vascular remodeling, that may contribute to brain recovery after 
stroke. 
Abbreviations: IL-1β, interleukin-1β; TNF-α, tumor necrosis factor- α; tPA, tissue 
plasminogen activator; LRP, LDL receptor related protein; NF-κB, nuclear factor κB, 
ROS, reactive oxygen species; NO, nitric oxide; (pro)MMP, (pro) matrix 
metalloproteinase. 
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